Micafungin: A review of its use in the prophylaxis and treatment of invasive Candida infections in pediatric patients

Pediatric Drugs

Volumn 11, Issue 4, 2009, Pages 271-291

  Carter, Natalie J ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; CAPSOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NIFEDIPINE; POSACONAZOLE; PREDNISOLONE; RAPAMYCIN; RIFAMPICIN; RITONAVIR; TACROLIMUS; UNCLASSIFIED DRUG; VORICONAZOLE;

ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIFUNGAL ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPERGILLOSIS; BILIRUBIN BLOOD LEVEL; BIOFILM; BODY WEIGHT; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KEFYR; CANDIDA TROPICALIS; CANDIDEMIA; CANDIDIASIS; CELL WALL; CHILL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FOLLOW UP; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IN VITRO STUDY; INJECTION SITE REACTION; JAPAN; LIVER DYSFUNCTION; LIVER FAILURE; LIVER FUNCTION TEST; LIVER METABOLISM; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PAIN; PHLEBITIS; POPULATION; PREMATURITY; PRIORITY JOURNAL; REVIEW; RIGOR; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREA BLOOD LEVEL; VISUAL DISORDER; VOMITING;

ANTIFUNGAL AGENTS; CANDIDIASIS; CHILD; ECHINOCANDINS; HUMANS; LIPOPEPTIDES;

EID: 69749127453     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.2165/00148581-200911040-00006     Document Type: Review

References (132)

1. Groll AH, McNeil Grist L. Current challenge in the diagnosis and management of invasive fungal infections: report from the 15th International Symposium on Infections in the Immunocompromised Host: Thessaloniki; 2008 Jun 22-25. Int J Antimicrob Agents 2009 Feb; 33 (2): 101-104
2. Cappelletty D, Eiselstein-McKitrick K. Reviews of therapeutics: the echinocandins. Pharmacology 2007; 27 (3): 369-388
3. Fridkin SK, Kaufman D, Edwards JR, et al. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995-2004. Pediatrics 2006 May; 117 (5): 1680-1687
4. Almirante B, Rodríguez D. Antifungal agents in neonates: issues and recommendations. Pediatr Drugs 2007; 9 (5): 311-321 (Pubitemid 47557113)
5. Tortorano AM, Peman J, Bernhardt H, et al. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004 Apr; 23 (4): 317-322 (Pubitemid 38669942)
6. Stamos JK, Rowley AH. Candidemia in a pediatric population. Clin Infect Dis 1995 Mar; 20 (3): 571-575
7. Levy I, Rubin LG, Vasishtha S, et al. Emergence of Candida parapsilosis as the predominant species causing candidemia in children. Clin Infect Dis 1998 May; 26 (5): 1086-1088 (Pubitemid 28215469)
8. Zaoutis TE, Argon J, Chu J, et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005 Nov; 41 (9): 1232-1239 (Pubitemid 41532664)
9. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003 Sep; 37 (5): 634-643 (Pubitemid 37100802)
10. Nucci M, Colombo AL, Silveira F, et al. Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 1998 Nov; 19 (11): 846-850
11. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002 Aug; 110 (2): 285-291 (Pubitemid 34833012)
12. Faix RG. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 1992 Feb; 11 (2): 88-93
13. Saxen H, Virtanen M, Carlson P, et al. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr Infect Dis J 1995 Sep; 14 (9): 776-781
14. Saiman L, Ludington E, Pfaller M, et al. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J 2000 Apr; 19 (4): 319-324 (Pubitemid 30213071)
15. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases (original studies). Pediatr Infect Dis J 1998 Jun; 17 (6): 504-508
16. Faix RG, Kovarik SM, Shaw TR, et al. Mucocutaneous and invasive candidiasis among very low birth weight (<1,500 grams) infants in intensive care nurseries: a prospective study. Pediatrics 1989 Jan; 83 (1): 101-107
17. Frattarelli D, Reed MD, Giacoia GP, et al. Antifungals in systemic neonatal candidiasis. Drugs 2004; 64 (9): 949-968
18. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000 Jan; 44 (1): 57-62
19. Melkusová S, Bujdáková H, Volleková A, et al. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis [letter]. Pharmazie 2004; 59 (7): 573-574 (Pubitemid 38962834)
20. Ikeda F, Tanaka S, Ohki H, et al. Role of micafungin in the antifungal armamentarium. Curr Med Chem 2007; 14 (11): 1263-1275
21. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006 Apr; 42 (8): 1171-1178
22. Groll AH, Walsh TJ. FK-463 Fujisawa Pharmaceutical Co Ltd. Curr Opin Anti Infect Drugs 2000; 2 (4): 405-412
23. Astellas Pharma Inc. Funguard® 25 mg for infusion; Funguard® 50 mg for infusion; Funguard® 75 mg for infusion (micafungin sodium for injection): Japanese prescribing information [online]. Available from URL: http://www.e-search.ne.jp/~jpr/PDF/ASTELLAS13.PDF [Accessed 2008 Apr 8]
24. Astellas Pharma US Inc. Mycamine® (micafungin sodium) for injection: US prescribing information [online]. Available from URL: http://www.fda.gov/ medwatch/safety/2007/Aug-PI/Mycamine-PI.pdf [Accessed 2008 Apr 8]
25. Astellas Pharma GmbH. Mycamine® 50 mg powder for solution for infusion: European prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/mycamine/H-734-PI-en.pdf [Accessed 2008 May 16]
26. Cross SA, Scott LJ. Micafungin: a review of its use in adults for the treatment of invasive or oesophageal candidiasis, and as prophylaxis against Candida infection. Drugs 2008; 68 (15): 2225-2255
27. Ostrosky-Zeichner L, Pfaller M, Diekma D, et al. A proposal for an antifungal susceptibility testing (AST) breakpoint for micafungin (MFG) and Candida: integration of AST surveys and correlation with clinical outcomes [abstract no. M-2020]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
28. Dannaoui E, Lortholary O, Raoux D, et al. In vitro activity of caspofungin and micafungin against 1038 yeasts isolates from France by EUCAST reference method [abstract no. P1974]. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy; 2007 Mar 31-Apr 3; Munich
29. Mochizuki N, Aibiki M, Matsumoto Y, et al. Evaluation of micafungin (MCFG) activity in serum, including serum synergism [abstract no. M-1598]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
30. Mochizuki N, Ishikawa J, Matsumoto Y, et al. Evaluation of micafungin antifungal activities in patient serum [abstract no.M-1818]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
31. Pai MP, Samples M, Mercier RC. Activity of flucytosine (F), micafungin (M), and voriconazole (V) in an in vitro pharmacodynamic model (PDM) of Candida spp. (CS) simulated endocardial vegetations (SEVs) [abstract no. M-1847]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
32. Pai MP, Samples M, Mercier RC. Candida albicans (CA) biofilm activity of flucytosine (F), liposomal amphotericin B (L-AmB), and micafungin (M) in an in vitro pharmacodynamic model (PDM) of simulated endocardial vegetations (SEVs) [abstract no. M-1859]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
33. Ali A, Vasquez G, Vager D, et al. Pharmacodynamics of echinocandins against Candida spp, including strains with reduced susceptibility to micafungin and caspofungin while retaining anidulafungin activity [abstract no. M-538]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
34. Wierman M, Obeid K, Baxa D, et al. Emergence of Candida glabrata isolates with reduced susceptibility to caspofungin and micafungin, but not anidulafungin [abstract no. M-512]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
35. Maki K, Morishita Y, Iguchi Y, et al. In vitro antifungal activity of FK463, a novel water-soluble echinocandin-like lipopeptide [abstract no. F-141]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-27; San Diego (CA)
36. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. (document M27-A3). Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Apr; 28 (14)
37. Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008 Jan; 46 (1): 150-156
38. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. 3rd informational supplement (document M27-S3). Wayne (PA): Clinical and Laboratory Standards Institute, 2008 Apr; 28 (15)
39. Takakura S, Fujihara N, Saito T, et al. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004 Feb; 53 (2): 283-289 (Pubitemid 38239963)
40. Müller F-MC, Kurzai O, Hacker J, et al. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis. J Antimicrob Chemother 2001 Nov; 48 (5): 713-715 (Pubitemid 33100318)
41. Ernst EJ, Roling EE, Petzold CR, et al. In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob Agents Chemother 2002 Dec; 46 (12): 3846-3853
42. Cantón E, Pemán J, Sastre M, et al. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii. Antimicrob Agents Chemother 2006 Aug; 50 (8): 2829-2832 (Pubitemid 44198707)
43. Heyn K, Tredup A, Salvenmoser S, et al. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani. Antimicrob Agents Chemother 2005 Dec; 49 (12): 5157-5159
44. Rodríguez MM, Ruiz M, Pastor FJ, et al. In vitro interaction of micafungin and fluconazole against Candida [letter]. J Antimicrob Chemother 2007 Jul; 60 (1): 188-190
45. Mariné M, Serena C, Pastor J, et al. In vitro activity of micafungin combined with itraconazole against Candida spp. Int J Antimicrob Agents 2007 Nov; 30 (5): 463-465
46. Kim M-N, Shin JH, Sung H, et al. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis 2009 Mar; 48 (6): e57-61
47. Rodríguez-Tudela JL, Barchiesi F, Bille J, et al. Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeasts. Clin Microbiol Infect 2003 Aug; 9 (8): 1-8
48. Paderu P, Garcia-Effron G, Balashov S, et al. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob Agents Chemother 2007 Jun; 51 (6): 2253-2256
49. Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002 Jun; 46 (6): 1773-1780 (Pubitemid 34535196)
50. Seidler M, Salvenmoser S, Müller F-MC. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections. Int J Antimicrob Agents 2006 Dec; 28 (6): 568-573
51. Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004 Feb; 53 (2): 386-389 (Pubitemid 38239980)
52. Mariné M, Serena C, Pastor FJ, et al. Combined antifungal therapy in a murine infection by Candida glabrata. J Antimicrob Chemother 2006 Dec; 58 (6): 1295-1298 (Pubitemid 44884157)
53. Olson JA, Adler-Moore JP, Smith PJ, et al. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005 Dec; 49 (12): 4895-4902
54. Hernandez S, López-Ribot JL, Najvar LK, et al. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained froma patientwith progressive Candida esophagitis. Antimicrob Agents Chemother 2004 Apr; 48 (4): 1382-1383 (Pubitemid 38405501)
55. Douglas CM, Foor F, Marrinan JA, et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-β-D-glucan synthase. Proc Natl Acad Sci USA 1994 Dec 20; 91 (26): 12907-12911
56. Douglas CM, Marrinan JA, Li W, et al. A Saccharomyces cerevisiae mutant with echinocandin-resistant 1,3-β-D-glucan synthase. J Bacteriol 1994 Sep; 176 (18): 5686-5696 (Pubitemid 24280502)
57. Douglas CM, D'Ippolito JA, Shei GJ, et al. Identification of the FKS1 gene of Candida albicans as the essential target of the 1,3-β-D-glucan synthase inhibitors. Antimicrob Agents Chemother 1997 Nov; 41 (11): 2471-2479
58. Park S, Kelly R, Nielsen Kahn J, et al. Specific substitutions in the echinocandin target Fks1p account for reduced susceptiblity of rare laboratory and clinical Candida sp. isolates. Antimicrob Agents Chemother 2005 Aug; 49 (8): 3264-3273 (Pubitemid 41060570)
59. Laverdière M, Lalonde RG, Baril J-G, et al. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J Antimicrob Chemother 2006 Apr; 57 (4): 705-708
60. Schuetzer-Muehlbauer M, Willinger B, Krapf G, et al. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol Microbiol 2003; 48 (1): 225-235 (Pubitemid 36411479)
61. Niimi K, Maki K, Ikeda F, et al. Overexpression of Candida albicans CDR1, CDR2, or MDR1 does not produce significant changes in echinocandin susceptiblity. Antimicrob Agents Chemother 2006 Apr; 50 (4): 1148-1155
62. Osherov N, May GS, Albert ND, et al. Overexpression of Sbe2p, a Golgi protein, results in resistance to caspfungin in Saccharomyces cerevisiae. Antimicrob Agents Chemother 2002 Aug; 46 (8): 2462-2469 (Pubitemid 34793450)
63. Stevens DA, Espiritu M, Parmar R. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob Agents Chemother 2004 Sep; 48 (9): 3407-3411 (Pubitemid 39129338)
64. Chamilos G, Lewis RE, Albert N, et al. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin- specific and Candida species-related differences. Antimicrob Agents Chemother 2007 Jun; 51 (6): 2257-2259 (Pubitemid 46903132)
65. Jacobsen MD, Whyte JA, Odds FC. Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro. Antimicrob Agents Chemother 2007 May; 51 (5): 1882-1884
66. Stevens DA, White TC, Perlin DS, et al. Studies of the paradoxical effect of caspofungin at high drug concentrations. Diagn Microbiol Infect Dis 2005 Mar; 51 (3): 173-178
67. Clemons KV, Espiritu M, Parmar R, et al. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob Agents Chemother 2006 Apr; 50 (4): 1293-1297
68. Baixench M-T, Aoun N, Desnos-Ollivier M, et al. Acquired resistance to echinocandins in Candida albicans: case report and review. J Antimicrob Chemother 2007 Jun; 59 (6): 1076-1083 (Pubitemid 47073317)
69. Mio T, Adachi-Shimizu M, Tachibana Y, et al. Cloning of the Candida albicans homolog of Saccharomyces cerevisiae GSC1/FKS1 and its involvement in β-1,3-glucan synthesis. J Bacteriol 1997 Jul; 179 (13): 4096-4105 (Pubitemid 27291036)
70. Hakki M, Staab JF, Marr KA. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob Agents Chemother 2006 Jul; 50 (7): 2522-2524 (Pubitemid 43993195)
71. Moudgal V, Little T, Boikov D, et al. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob Agents Chemother 2005 Feb; 49 (2): 767-769 (Pubitemid 40175691)
72. Messer SA, Diekema DJ, Boyken L, et al. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006 Feb; 44 (2): 324-326 (Pubitemid 43222217)
73. Borg-von Zepelin M, Zaschke K, Gross U, et al. Effect of micafungin (FK463) on Candida albicans adherence to epithelial cells. Chemotherapy 2002 Jul; 48 (3): 148-153
74. Gil-Lamaignere C, Salvenmoser S, Hess R, et al. Micafungin enhances neutrophil fungicidal functions against Candida pseudohyphae. Antimicrob Agents Chemother 2004 Jul; 48 (7): 2730-2732
75. Freire A, Arrieta A, Stevenson P, et al. Pharmacokinetics of micafungin in paediatric patients with invasive candidiasis and candidaemia [abstract no. A-772 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
76. Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005 Aug; 49 (8): 3317-3324
77. Tabata K, Katashima M, Kawamura A, et al. Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections. Biol Pharm Bull 2006 Aug; 29 (8): 1706-1711 (Pubitemid 44166376)
78. Heresi GP, Gerstmann DR, Reed MD, et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006 Dec; 25 (12): 1110-1115
79. Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009 May; 28 (5): 412-415
80. Benjamin DK, Smith PB, Arrieta A, et al. Safety and pharmacokinetics (PK) of repeat-dose micafungin (MICA) in neonates [abstract no. A-012 plus poster]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25-28; Washington (DC)
81. Joseph JM, Jain R, Danziger LH. Micafungin: a new echinocandin antifungal. Pharmacotherapy 2007; 27 (1): 53-67
82. Arrieta A. Overview of paediatric experience with micafungin [abstract]. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy; 2007 March 31-Apr 3;Munich
83. Steinbach WJ, Benjamin DK. New antifungal agents under development in children and neonates. Curr Opin Infect Dis 2005 Dec; 18 (6): 484-489
84. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetic and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008 Jan; 197 (1): 163-171 (Pubitemid 351263481)
85. Hebert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J Clin Pharmacol 2005 Oct; 45 (10): 1145-1152
86. Hebert MF, Blough DK, Townsend RW, et al. Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005 Sep; 45 (9): 1018-1024 (Pubitemid 41192360)
87. Undre N, Stevenson P, Wilbraham D, et al. Amphotericin B does not affect the pharmacokinetics of micafungin (FK463) [abstract no. P971 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy; 2007 Mar 31-Apr 3; Munich
88. Undre N, Stevenson P, Brooks A, et al. Itraconazole does not affect the pharmacokinetics of micafungin (FK463) [abstract no. P970 plus poster]. 17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy; 2007 Mar 31-Apr 3; Munich
89. Hebert MF, Townsend RW, Austin S, et al. Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers. J Clin Pharmacol 2005 Aug; 45 (8): 954-960 (Pubitemid 41060236)
90. Keirns J, Sawamoto T, Holum M, et al. Steady-state pharmacokinetics of micafungin and voriconazole after separate and concomitant dosing in healthy adults. Antimicrob Agents Chemother 2007 Feb; 51 (2): 787-790 (Pubitemid 46185309)
91. Undre NA, Stevenson P, Amakye DD. Rifampicin and ritonavir do not affect the pharmacokinetics of micafungin (FK463), an echninocandin antifungal [abstract no. P1037]. Clin Microbiol Infect 2004 May; 10 Suppl. 3: 279
92. Narumi S, Hakamada K, Toyoki Y, et al. Influence of antifungal agents on trough level of tacrolimus [abstract no. 1247]. Am J Transplant 2005; 5 Suppl. 11: 474
93. Shimoeda S, Ohta S, Kobayashi H, et al. Analysis of the blood level of micafungin involving patients with hematological diseases: new findings regarding combination therapy with tacrolimus. Biol Pharm Bull 2005 Mar; 28 (3): 477-480 (Pubitemid 40879971)
94. Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring concentrations in the cerebrospinal fluid. Scand J Infect Dis 2007; 39 (4): 344-383 (Pubitemid 46567386)
95. Groll AH, Mickiene D, Petraitis V, et al. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob Agents Chemother 2001 Dec; 45 (12): 3322-3327
96. Niwa T, Yokota Y, Tokunaga A, et al. Tissue distribution after intravenous dosing of micafungin, an antifungal drug, to rats. Biol Pharm Bull 2004 Jul; 27 (7): 1154-1156 (Pubitemid 41701780)
97. Krishna G, Vickery D, Ma L, et al. Effect of posaconazole on pharmacokinetics (PK) of caspofungin and micafungin [abstract no. A-015]. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America; 2008 Oct 25-28; Washington (DC)
98. Sakaeda T, Iwaki K, Kakumoto M, et al. Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005 Jun; 57 (6): 759-764 (Pubitemid 40694884)
99. Queiroz-Telles F, Berezin E, Leverger G, et al. Micafungin versus liposomal amphotericin B for pediatric patients with invasive candidiasis. Pediatr Infect Dis J 2008 Sep; 27 (9): 820-826
100. Kuse E-R, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007 May 5; 369 (9572): 1519-1527 (Pubitemid 46670281)
101. van Burik J-A, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004 Nov 15; 39: 1407-1416 (Pubitemid 39518200)
102. European Medicines Agency. Assessment report for mycamine (EMEA/H/C/000734) [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/mycamine/H-734-en6.pdf [Accessed 2008 Aug 14]
103. Denning DW, Marr KA, Lau WM, et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006 Nov; 53 (5): 337-349
104. Arrieta A, Seibel NL, Walsh TJ, et al. Micafungin for the treatment of pediatric invasive fungal infections [abstract no. P313 plus poster]. 29th International Symposium on Intensive Care and Emergency Medicine; 2009 Mar 24-27; Brussels
105. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, et al. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 2005 Oct; 24 (10): 654-661 (Pubitemid 41667052)
106. Arrieta A, Maddison P, Groll AH. Micafungin in pediatric patients: assessment of safety in clinical trials [abstract no. M-1162 plus poster]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17-20; Chicago (IL)
107. Pappas PG. Invasive candidiasis. Infect Dis Clin North Am 2006 Sep; 20 (3): 485-506
108. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis 2004 Jan; 38 (2): 161-189
109. Herbrecht R, Flückiger U, Gachot B, et al. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur JCancer Suppl 2007 Jul; 5 (2): 49-59 (Pubitemid 47187744)
110. Merck Sharp & Dohme Ltd. Cancidas 50 mg powder for concentrate for solution for infusion: EU prescribing information [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=12843 [Accessed 2009 Jan 12]
111. Gilead Sciences Ltd. Ambisome®: UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinterFriendly.asp?documentid=1236 [Accessed 2008 Apr 8]
112. Cephalon Limited. Abelcet®: UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinterFriendly.asp?documentid=2133 [Accessed 2008 Apr 8]
113. Beacon Pharmaceuticals. Amphocil™ 100 mg: UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk/emc/ assets/c/html/displayDocPrinterFriendly.asp?documentid=18414 [Accessed 2008 Apr 8]
114. E. R. Squibb & Sons Limited. Fungizone® intravenous: UK prescribing information [online]. Available from URL: http://emc.medicines.org. uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=559 [Accessed 2008 Apr 8]
115. Pfizer Limited. Diflucan™ capsules 50 mg and 200 mg, powder for oral suspension 50 mg/ml and 200 mg/ml, intravenous infusion 2mg/ml [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinterFriendly.asp?documentid=1459 [Accessed 2008 Apr 8]
116. Hospira UK Ltd. Fluconazole 2mg/ml intravenous infusion [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/ displayDocPrinterFriendly.asp?documentid=16792 [Accessed 2008 Apr 8]
117. Valeant Pharmaceuticals Ltd. Ancotil® 2.5g/250 ml solution for infusion: UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp? documentid=6215 [Accessed 2008 Apr 8]
118. Pfizer Limited. Vfend® 50 mg and 200 mg film-coated tablets, Vfend® 200mg powder for solution for infusion, Vfend® 40 mg/ml powder for oral suspension [online]. Available from URL: http://emc.medicines.org.uk/ emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=10059 [Accessed 2008 Apr 8]
119. Wong-Beringer A, Kriengkauykiat J. Systemic antifungal therapy: new options, new challenges. Pharmacotherapy 2003; 23 (11): 1441-1462 (Pubitemid 37315035)
120. Blyth CC, Palasanthiran P, O'Brien TA. Antifungal therapy in children with invasive fungal infections: a systematic review. Pediatrics 2007 Apr; 119 (4): 772-784 (Pubitemid 46556677)
121. X-Gen Pharmaceuticals Inc. Amphotericin B for injection USP: US prescribing information [online]. Available from URL: http://www.x-gen.us/ Injectables/Amphotericin%20B/Amphotericin-files/insert/Amphotericin-pi. pdf [Accessed 2008 Apr 8]
122. Slavin MA, Szer J, Grigg AP, et al. Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections. Intern Med J 2004 Apr; 34 (4): 192-200 (Pubitemid 38651040)
123. Pfizer Inc. Vfend® I.V. (voriconazole) for injection, Vfend® tablets (voriconazole), Vfend® (voriconaole) for oral suspension [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/021266s023,
124. Denning DW, Kibbler CC, Barnes RA. British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections. Lancet Infect Dis 2003 Apr; 3 (4): 230-240
125. Böhme A, Ruhnke M, Buchheidt D, et al. Treatment of fungal infections in hematology and oncology: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003 Oct; 82 Suppl. 2: S133-40 (Pubitemid 37265300)
126. Maertens JA, Frère P, Lass-Flörl C, et al. Primary antifungal prophylaxis in leukaemia patients. Eur J Cancer 2007 Jul; 5 (2): 43-48 (Pubitemid 47193191)
127. Maertens J, Frère P, Lass-Flörl C, et al. 2007 update of the ECIL-1 guidelines for antifungal prophylaxis in leukemia patients, including allogeneic HSCT recipients: oral presentation [online]. Available from URL: http://www.eortc.be/services/unit/idg/documents/08.Antifungalprophylaxis.pdf [Accessed 2008 Sep 10]
128. Centers for Disease Control and Prevention, Infectious Diseases Society of America, and the American Society of Blood and Bone Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2000 Dec; 6 (6 Suppl. 1): 7-83
129. Pfizer Inc. Ecalta® 100 mg powder and solvent for concentrate for solution for infusion: EU prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ecalta/H-788-PI-en.pdf [Accessed 2008 Sep 16]
130. Merck & Co. Inc. Cancidas® (caspofungin acetate) for injection: highlights of US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/021227s021lbl.pdf [Accessed 2009 Jan 12]
131. Pfizer Inc. Eraxis™ (anidulafungin) for injection: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/ 2007/021632s006lbl.pdf [Accessed 2009 Jan 12]
132. Cornely OA, Sidhu M, Odeyemi I, et al. Economic analysis of micafungin versus liposomal amphotericin B for treatment of candidaemia and invasive candidiasis in Germany. Curr Med Res Opin 2008; 24 (6): 1743-1753 (Pubitemid 351929071)